Citations

Clear

3030 citation(s) found for "Susan, M".

The Influence of Depressive and Manic Symptoms on Suicidal Ideation in Mixed Mood States
Macellaro, Monica , Kelly, Carlton Max, Lyu, Jihun , McElroy, Susan L., Nolen, Willem A., Keck, P E, Post, R M, Suppes, Trisha, Cafaro, Rita , Kelly, Carlton Max, Ostacher, Michael J. , Dell’Osso, Bernardo Maria , Frye, Mark A., Kupka, Ralph , McElroy, Susan L. , Post, Robert M. , Grunze, Heinz

Mayo Clinic

No container title available | May 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6551903/v1 Get It

Abstract Background: While bipolar disorder is strongly linked to an increased risk of suicide, recent evidence has challenged the assumption that mixed symptoms play a distinct role in suicidal ideation beyond depressive severity. This study examines how depressive, hypo/manic, and mixed features influence suicidal ideation in individuals with bipolar disorder. Data from 903 participants in the Stanley Foundation Bipolar Network (1995–2002) were analyzed to assess associations between mood states, classified by the Inventory of Depressive Symptomatology–Clinician-Rated (IDS-C) and the Young Mania Rating Scale (YMRS), and suicidal ideation, measured using IDS-C item 18, using generalized estimating equations. Results: Depressive symptoms were strongly associated with suicidal ideation (OR = 21.98, 95% CI: 15.31–31.54). Moderate hypo/manic symptoms also conferred risk (OR = 3.11, 95% CI: 1.51–6.49), and milder hypo/mania showed a weaker but significant association (OR = 1.74, 95% CI: 1.05–2.89). The highest suicidal ideation was observed in individuals with hypo/mania featuring mixed symptoms (OR = 29.43), exceeding that of depression or depression with mixed features (OR = 21.98). However, findings diverged based on modeling approach: in continuous predictor models, SI was driven solely by depressive symptom severity, with no significant association observed for hypo/mania or its interaction with depression. In contrast, when mood states were categorized using clinically meaningful thresholds, hypo/mania with mixed features emerged as a distinct contributor to suicidal ideation risk. Conclusion: These findings underscore the need for integrating both dimensional and categorical approaches to mood state classification in research on suicidality in bipolar disorder.
Delphi Panel for the Development of Diagnostic Criteria for Metastatic Cutaneous Crohn Disease
Ebriani, Joseph, Santiago-Soltero, Karla , Anshelevich, Ellen, Shields, Bridget E. , Charrow, Alexandra , Panel, The Metastatic Cutaneous Crohn’s Disease Delphi, Burgin, Susan , Cices, Ahuva , Coromilas, Alexandra, Rosenbach, Misha , Shaw, Katharina S. , Watson, Alice J., Ebriani, Joseph , Dalal, Rahul S. , Panel, The Metastatic Cutaneous Crohn’s Disease Delphi, Agrawal, Manasi , Alavi, Afsáneh , Cowen, Edward W , Goldfarb, Noah , Hsiao, Jennifer L. , McGee, Jean S. , Ortega‐Loayza, Alex G. , Porter, Martina Lee , Wanat, Karolyn A. , Wong, Serre-Yu

Mayo Clinic

JAMA Dermatology | May 7, 2025 | Volume: 161 | Issue: 6 | Pages: 642

10.1001/jamadermatol.2025.1115 | PMID 40332924 Get It

ImportanceMetastatic cutaneous Crohn disease (MCD) is a rare condition for which there are currently no published diagnostic criteria. Formal MCD diagnostic criteria will expand clinical care and research by enabling future diagnostic code validation, crystallizing a more uniform disease entity for the purposes of translational research, and allowing the development of more formalized outcome measures aimed at treatment response.ObjectiveTo define a set of criteria for the diagnosis of MCD.Evidence ReviewIn this consensus statement, a panel of experts on MCD and related conditions was assembled. Their opinions were gathered regarding the clinical and histologic findings that are sufficient, necessary, and highly suggestive of MCD through serial survey. Subsequent surveys were continued until consensus was achieved. Sufficient was defined as a feature that, if noted, would enable diagnosis of MCD without any other signs, symptoms, or testing. Necessary was defined as a feature that must be present to establish a diagnosis of MCD. Highly suggestive referred to any other features that were indicative of MCD but did not qualify as sufficient or necessary to diagnose MCD.FindingsOf 24 experts invited, 19 agreed to participate, with a 79% to 100% response rate across 5 rounds conducted. Five patients were also invited to participate, but none opted to participate, citing lack of clinical expertise and time concerns. The experts were all from the US; 5 (26%) have practiced medicine for 0 to 5 years, 5 (26%) practiced for 6 to 10 years, 6 (32%) practiced for 11 to 15 years, and 3 (16%) practiced for more than 20 years. A total of 18 experts (95%) worked in an academic practice setting. There was consensus agreement that MCD could present as oral disease, genital disease, or, rarely, in another location. Consensus was achieved on 2 major and 5 minor criteria for genital/other subtypes of MCD and 5 minor criteria for oral MCD. There was consensus that, while there are some pathological findings that are highly suggestive of MCD, histologic criteria are not necessary for diagnosis.Conclusions and RelevanceA panel of experts reached consensus on the diagnostic criteria for MCD described in this study. These criteria include major and minor clinical criteria, along with histopathological criteria for the diagnosis of genital and oral MCD. This consensus is a crucial step in the diagnosis of and future treatment development for MCD, a rare and clinically understudied condition.
Differences in Alzheimer's disease blood biomarker stability: Implications for the use of tau/amyloid ratios
Schuder, Bethany J., Ashrafzadeh‐Kian, Susan , Gronquist, Tina, Bornhorst, Joshua A. , Algeciras‐Schimnich, Alicia , Algeciras-Schimnich, Alicia , Figdore, Daniel J. , Ashrafzadeh-Kian, Susan, Bornhorst, Joshua

Mayo Clinic

Alzheimer's & Dementia | May 1, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.70173 | PMID 40308118 Get It

AbstractINTRODUCTIONWe compare the stability of phosphorylated tau (p‐tau)217, amyloid beta (Aβ)42, Aβ40, Aβ42/40, and p‐tau217/Aβ42 at different storage temperatures.METHODSTen ethylenediaminetetraacetic acid–plasma sample aliquots stored at frozen, refrigerated, and ambient temperatures were tested at various timepoints up to 30 days. The mean percent change from baseline was calculated.RESULTSAβ42 and Aβ40 concentrations decreased by >15% after 6 hours at ambient temperature and after 24 hours refrigerated, while p‐tau217 remained stable over 72 hours with < 10% deviation from baseline at either storage temperature. The Aβ42/40 ratio remained relatively constant as each analyte concentration decreased concurrently, while the p‐tau217/Aβ42 ratio deviated from baseline over time. All biomarkers were stable up to 30 days frozen.DISCUSSIONDifferences in the stability of Aβ42 and p‐tau217 may lead to altered p‐tau217/Aβ42 ratio results if samples are not handled properly during the pre‐analytical testing phase. Ideally, samples should be frozen promptly and sent to the laboratory frozen.Highlights Plasma phosphorylated tau (p‐tau)217, amyloid beta (Aβ)42, Aβ40, Aβ42/40, and p‐tau217/Aβ42 stability was assessed. P‐tau217 was stable, but Aβ42 and Aβ40 started decreasing by 6 hours at ambient temperature. The analyte stability differences led to falsely increased p‐tau217/Aβ42 ratios. Increases > 15% were seen in p‐tau217/Aβ42 after 6 hours at ambient temperature or 24 hours at 4°C.
UNISOM: Unified Somatic Calling and Machine Learning-based Classification Enhance the Discovery of CHIP
Tian, Shulan , Jenkinson, Garrett , Ferrer, Alejandro Tiana, Yan, Huihuang , Morales‐Rosado, Joel A. , Wang, Kevin L. , Lasho, Terra L. , Yan, Benjamin B. , Baheti, Saurabh , Olson, Janet E. , Patnaik, Mrinal M. , Klee, Eric W. , Ferrer, Alejandro , Ferrer, Alejandro , Baughn, Linda B , Ding, Wei , Slager, Susan L , Patnaik, Mrinal , Lazaridis, Konstantinos N , Klee, Eric W , Olson, Janet E , Lasho, Terra L , Tian, Shulan , Morales-Rosado, Joel A , Baughn, Linda B. , Slager, Susan L. , Lazaridis, Konstantinos N.

Mayo Clinic

Genomics, Proteomics & Bioinformatics | April 29, 2025 | Volume: 23 | Issue: 2 | Pages: No page available

10.1093/gpbjnl/qzaf040 | PMID 40300108 Get It

Abstract Clonal hematopoiesis (CH) of indeterminate potential (CHIP), driven by somatic mutations in leukemia-associated genes, confers increased risk of hematologic malignancies, cardiovascular disease, and all-cause mortality. In blood of healthy individuals, small CH clones can expand over time to reach 2% variant allele frequency (VAF), the current threshold for CHIP. Nevertheless, reliable detection of low-VAF CHIP mutations is challenging, often relying on deep targeted sequencing. Here, we present UNISOM, a streamlined workflow for enhancing CHIP detection from whole-genome and whole-exome sequencing data that are underpowered, especially for low VAFs. UNISOM utilizes a meta-caller for variant detection, in couple with machine learning models which classify variants into CHIP, germline, and artifact. In whole-exome sequencing data, UNISOM recovered nearly 80% of the CHIP mutations identified via deep targeted sequencing in the same cohort. Applied to whole-genome sequencing data from Mayo Clinic Biobank, it recapitulated the patterns previously established in much larger cohorts, including the most frequently mutated CHIP genes and predominant mutation types and signatures, as well as strong associations of CHIP with age and smoking status. Notably, 30% of the identified CHIP mutations had &lt; 5% VAFs, demonstrating its high sensitivity toward small mutant clones. This workflow is applicable to CHIP screening in population genomic studies. The UNISOM pipeline is freely available at https://github.com/shulanmayo/UNISOM and https://ngdc.cncb.ac.cn/biocode/tool/7816.
Establishing the content validity of patient-reported outcome measures used in neuro-oncology based on the WHO ICF framework: Part of the RANO-PRO initiative
Asogwa, Ogechukwu A , Walbert, Tobias , Arons, David, Blakeley, Jaishri O. , Coomans, Marijke B , Brown, Paul D. , Bulbeck, Helen , Chang, Susan M. , Coens, Corneel , Grant, Robin, Jalali, Rakesh , Koekkoek, Johan A F , Panda, Pankaj Kumar , Leach, Danielle, Mendoza, Tito R. , Nayak, Lakshmi , Oliver, Kathy , Reijneveld, Jaap C. , Taylor, Jennie , Wen, Patrick Y. , Taphoorn, Martin , Walbert, Tobias , Blakeley, Jaishri O , Bulbeck, Helen , Gilbert, Mark R , Grant, Robin , Jalali, Rakesh , Nayak, Lakshmi , Le Rhun, Emilie , Taylor, Jennie W , Weller, Michael , Mendoza, Tito , Koekkoek, Johan A F , Dirven, Linda , Armstrong, Terri S. , Bent, Martin J. van den , Chang, Susan Marina , Gilbert, Mark R. , Leeper, Heather , Rhun, Émilie Le , Rubinstein, Larry , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | April 28, 2025 | Volume: 27 | Issue: 9 | Pages: 2399-2414

10.1093/neuonc/noaf108 | PMID 40293144 Get It

Abstract Background Instruments to assess patient-reported outcomes (PRO) should generate high-quality evidence. Reliable PRO evidence is essential to policymakers, in conjunction with outcomes such as survival and radiological response, to understand the net clinical benefit of antitumor treatments. This study aimed to establish the content validity of 215 identified PRO measures used in patients with brain tumors. Methods A survey (n = 148 items) was developed reflecting aspects of the WHO International Classification of Functioning, Disability, and Health (ICF) framework. Patients with brain tumors, their proxies, and healthcare professionals (HCPs) were asked to rate each survey item on relevance. An item was considered a relevant issue if ≥25% of the patients or proxies or ≥50% of the HCPs considered that item to be an issue. Next, all items in the identified PRO measures were linked to ICF and relevant items in the survey, and the percentage of content coverage was calculated. Results In total, 114 patients, 71 proxies, and 65 HCPs from different countries completed the survey. Fifty-six of 148 (37.8%) items in the survey were considered relevant. The most important aspects mentioned by both patients and proxies were difficulty concentrating, difficulty remembering, multitasking, and handling stress. Depending on the definition, between 35% and 49% of PRO measures were considered to have sufficient content validity (≥80% coverage). Conclusion The content validity was insufficient in more than half of the identified PRO measures, particularly multidimensional measures. Future research should investigate whether different approaches to PRO assessment better meet the needs of all stakeholders.
Multisociety guidance for sterilization and high-level disinfection
Shenoy, Erica S. , Weber, David J. , McMullen, Kathleen , Rubin, Zachary, Sampathkumar, Priya , Schaffzin, Joshua K. , Sickbert-Bennett, Emily , Washer, Laraine , Yokoe, Deborah S. , Calderwood, Audrey H. , Chinn, Raymond , Day, Michelle, Garcia‐Houchins, Sylvia, Javaid, Waleed , Klacik, Susan, Kyle, Erin , Murthy, Rekha , Wood, Amber , Rutala, William A.

Mayo Clinic

Infection Control & Hospital Epidemiology | April 28, 2025 | Volume: 46 | Issue: 6 | Pages: 561-583

10.1017/ice.2025.41 | PMID 40289578 Get It

Abstract This multisociety infection prevention guidance document was developed for individuals and organizations that engage in sterilization or high-level disinfection (HLD). It was endorsed by SHEA, APIC, ASGE, IDSA, and SGNA. This guidance is based on a synthesis of published scientific evidence, theoretical rationale, current practices, practical considerations, writing group consensus, and consideration of potential harm when applicable. The supplementary material includes a summary of recommendations. The guidance provides an overview of the Spaulding Classification and considerations around manufacturers’ instructions for use (MIFUs). Its recommendations address: point-of-use treatment prior to sterilization or HLD, preparation of reusable medical devices at the location of processing, sterilization, and immediate use steam sterilization (IUSS), HLD of lumened and non-lumened devices, processing of reusable medical devices used with lubricating or defoaming agents, monitoring for effectiveness of processing, handling of devices after HLD, augments and alternatives to HLD, processing of investigational devices, tracking of reusable medical devices, and approaches to implementation.
144. A Video-based Learning Module in an Effective Way to Teach the Interpretation of Pre-operative Electrodiagnostic Studies
Llaneras, Noah S. , Taylor, R. W., Orr, Jonah, Wu, Kitty Y. , Pripotnev, Stahs , Mackinnon, Susan E., Zhang, Justin K.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 25, 2025 | Volume: 13 | Issue: S1 | Pages: 99-99

10.1097/01.gox.0001112524.79751.30 Get It

Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites
Bajaj, Jasmohan S. , Reddy, K. Rajender , Keaveny, Andrew P. , Porayko, Michael K. , Koch, David , Thuluvath, Paul J. , Angeli, Paolo, Janardhan, Sujit , Zhang, Jeffrey , Clausen, Susan, Dauphinée, Elisa, Palumbo, Joseph, Markham, Penelope , Weinberg, Ethan M , Rajender Reddy, K , Keaveny, Andrew P , Porayko, Michael K , Koch, David , Angeli, Paolo , Orman, Eric S , Palumbo, Joseph M , Weinberg, Ethan M. , Simonetto, Douglas A. , Angeli, Paolo , Orman, Eric S. , Clausen, Susan

Mayo Clinic

Liver Transplantation | April 24, 2025 | Volume: 31 | Issue: 10 | Pages: 1202-1214

10.1097/lvt.0000000000000623 | PMID 40272365 Get It

Refractory ascites often requires therapeutic paracentesis, which is associated with potential risks and diminished quality of life. Terlipressin is a vasopressin analog that is indicated for i.v. bolus injection for hepatorenal syndrome, with the potential to reduce large-volume ascites and its complications. Continuous infusion of terlipressin is associated with fewer adverse effects than bolus dosing. The efficacy and safety of continuous infusion of a novel liquid formulation of terlipressin acetate (BIV201) were evaluated in this open-label phase 2 study. Patients with cirrhosis and refractory ascites were randomly assigned (2:1) to receive two 28-day cycles of continuous infusion BIV201 plus standard of care (SOC) separated by a ≤56-day washout (n=10), or SOC alone (n=5). Data analysis was limited by the small sample size and confounded by a potential interaction with gabapentinoids in the BIV201+SOC group. Nonetheless, there were differences in favor of BIV201+SOC versus SOC in the coprimary efficacy endpoints and several quality of life assessments. The beneficial effects of BIV201 on liver complications (mean: 90% CI; BIV201-completers=2.87: 1.51; 5.46 vs. SOC=2.38: 1.20; 4.73) and the change in cumulative ascites (mean: 90% CI; BIV201-completers=−10.76: −26.51; 5.00 vs. SOC=−4.99: −21.95; 11.97) were more pronounced versus SOC in the 5 BIV201+SOC patients who completed both treatment cycles. There were also greater improvements in exploratory quality of life assessments and the percent change in therapeutic paracenteses with BIV201+SOC (−27.94±41.80) versus SOC (−16.67±45.64). Despite the high rate of hyponatremia in the BIV201+SOC group (4/10 patients), the safety profile suggested that continuous BIV201 infusion was well tolerated. These findings support further development of BIV201 in confirmatory trials.